Product Details

Manufacturer: Fujirebio

EIA for the quantitative determination of ß-amyloid(1-42) in human cerebrospinal fluid (CSF) – a diagnostic marker of Alzheimer’s disease

Unit: 96 tests
Code: 81576
For sale in the following countries: GBR, NIR

Alzheimer’s, the most common form of dementia, is a neurodegenerative disorder histologically characterized by the accumulation of intracellular neurofibrillary tangles and extracellular amyloid plaques throughout the cortical and limbic brain regions. The ultrastructure of neurofibrillary tangles is made up of paired helical filaments composed mainly of abnormally hyperphosphorylated TAU protein (Phospho-TAU). The major
components of the amyloid deposits are the 40- and 42-amino acid-long β-amyloid peptides, which are derived from integral membrane-bound amyloid precursor protein.

The INNOTEST β-AMYLOID(1-42) is a solid-phase enzyme immunoassay in which the amyloid peptide is captured by a first monoclonal antibody, 21F12 (IgG2a). CSF samples are added and incubated with a biotinylated antibody, 3D6 (IgG2b). This antigen-antibody complex is then detected by a peroxidase-labeled streptavidin. After addition of substrate working solution, samples will develop a color. The colour intensity is a measure for the amount of human β-amyloid(1-42) protein in the sample.


Enquire about this product

Launch Diagnostics is a leading supplier of diagnostic reagents and equipment to health services of European countries, and a licensed reseller and distributor of INNOTESTTM ß-AMYLOID(1-42). If you are interested in this product, please contact us or use the enquiry form.

See our full range of diagnostic tests and controls